News Column

Marina Biotech Restores Compliance with Exchange Act Reporting Obligations

August 26, 2014

Marina Biotech said that the Company has become current with respect to its obligation to file reports with the Securities and Exchange Commission under Section 13 of the Securities Exchange Act of 1934, having filed its Annual Reports on Form 10-K for the fiscal years ended December 31, 2012 and December 31, 2013, its Quarterly Reports on Form 10-Q for the first three quarters of the 2013 fiscal year, and its Quarterly Reports on Form 10-Q for the first and second fiscal quarters of 2014 over the past thirty days.

According to a Company release, in addition, the Company is using its proprietary nucleic acid drug discovery platform to refocus research and developments efforts on expanding its clinical pipeline with the addition of two orphan disease programs.

"The last two years have been very challenging for the company, but as a result of recent progress, I believe we are solidly on a turnaround path and well on our way to building significant shareholder value," stated J. Michael French, president & CEO of Marina Biotech. "In 2010, we began executing an aggressive strategy to consolidate key intellectual property and technologies necessary to create a broad nucleic acid-based drug discovery platform. I believe that strategy continues to be successful and has resulted in a platform and capability unparalleled within the industry. Thus far, our platform and efforts have resulted in: (1) the only orally administered nucleic acid therapeutic, CEQ508 for the treatment of Familial Adenomatous Polyposis, in clinical development; (2) the only technology, SMARTICLES, delivering both a single-stranded and a double-stranded oligonucleotide compound in ongoing clinical trials; and (3) the only company with the freedom-to-operate to develop any number of nucleic acid-based compounds, such as: small interfering RNA, microRNA mimics, microRNA antagonists, and antisense oligonucleotides that target broad RNA-based mechanisms of action, including: RNA interference, mRNA translational inhibition, exon skipping, microRNA replacement, microRNA inhibition, and steric blocking."

French continued, "In terms of delivery, we believe the combined clinical experience of ProNAi and Mirna demonstrates that SMARTICLES has the potential to provide significant advancements in the delivery of oligonucleotide-based compounds. Further, we believe our unique, multi-faceted approach is clearly applicable in the development of therapeutics to treat complex diseases particularly orphan diseases and, as a result, sets us apart from our competitors. Moving forward we intend to expand our clinical pipeline with the addition of two orphan disease programs: myotonic dystrophy and Duchenne's muscular dystrophy. Our goals are to: (1) receive approval for and then commercialize CEQ508 in the United States and to license the compound outside the U.S. and (2) achieve human proof-of-concept in myotonic dystrophy and Duchenne's muscular dystrophy and then to partner those opportunities for further development and commercialization."

More information and complete details:

www.marinabio.com

((Comments on this story may be sent to newsdesk@closeupmedia.com))


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Professional Services Close - Up


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters